Journal
SCIENTIFIC REPORTS
Volume 13, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-023-44590-w
Keywords
-
Categories
Ask authors/readers for more resources
This study investigated the effect of Hippophae rhamnoides L. (HRP) on the activity of CYP2D6 in rats with BCG-induced immunological liver injury. The results showed that HRP restored the metabolic function of the liver by reversing the downregulation of CYP2D6 through inhibition of NF-kappa B signal transduction and regulation of the cAMP/PKA/CREB/CYP2D6 pathway. HRP could be considered as an alternative clinical drug for treating hepatitis B and other immune-related liver diseases.
In this study, we investigated the effect of Hippophae rhamnoides L. (HRP) on the activity of CYP2D6 via the CAMP/PKA/NF-kappa B pathway in rats with Bacille Calmette-Guerin (BCG)-induced immunological liver injury. BCG (125 mg/kg) was injected to establish the rat model of liver injury. HRP was administered intragastrically for one week as the intervention drug. Proteomics techniques were used to analyze protein expression levels, obtaining a comprehensive understanding of the liver injury process. ELISA or western blotting was used to detect specific protein levels. Dextromethorphan was detected using high-performance liquid chromatography to reflect the metabolic activity of CYP2D6. BCG downregulated the expression of CYP2D6, cAMP, PKA, I kappa B, and P-CREB and upregulated that of NF-kappa B, IL-1 beta, TNF-alpha, and CREB in the liver; HRP administration reversed these effects. Therefore, HRP may restore the metabolic function of the liver by reversing the downregulation of CYP2D6 through inhibition of NF-kappa B signal transduction and regulation of the cAMP/PKA/CREB/CYP2D6 pathway. These findings highlight the role of HRP as an alternative clinical drug for treating hepatitis B and other immune-related liver diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available